This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS
|| List of recent Leukemia-related patents
|Methods of treating hematological malignancies with notch1 antibodies|
Notch1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human notch1 and methods of treating chronic lymphocytic leukemia (cll), hairy cell leukemia, chronic myelogenous leukemia (cml), nonhodgkin lymphoma, diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), or cutaneous t-cell lymphoma (ctcl) in a subject, comprising administering a therapeutically effective amount of a notch1-binding antibody to the subject are also disclosed.
Oncomed Pharmaceuticals, Inc.
|Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells|
Substance p antagonists and, in particular, non-peptidic nk1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human hodgkin's lymphoma km-h2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human burkitt's lymphoma, human lung carcinoma, human ewing's sarcoma, human glioma and human osteosarcoma.. .
Antagonista Enekauno, S.l.
|Methods of treating pediatric acute lymphoblastic leukemia with an anti-cd22 immunotoxin|
The present invention provides methods for the treatment of acute lymphoblastic leukemia (all) in pediatric patients using an anti-cd22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (vl) chain linked to a variable heavy (vh) which is genetically fused to a therapeutic moiety comprising a pseudomonas exotoxin a pe38 fragment.
|Enhancement of allogeneic hematopoietic stem cell transplantation|
Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (hct), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. Treatment of anemias, thalassemias, autoimmune conditions, and the like.
The Board Of Trustees Of The Leland Stanford Junior University
|Method of treating leukemia|
The present invention relates to methods of treating disorders in which dot1l-mediated protein methylation plays a part, such as cancer, by administering dot1l inhibitor compounds and pharmaceutical compositions to subjects in need thereof.. .
|Agent for treating or inhibiting recurrence of acute myeloid leukemia|
Wherein ar1 and ar2 each represent aryl or heteroaryl; l represents o, s, nh, nhco, or conh; x represents ch or n; y represents c1-3-alkylene; z1 represents hydrogen, c1-6-alkyl, amino-c1-6-alkyl, c1-6-alkylamino-c1-6-alkyl, di(c1-6-alkyl)amino-c1-6-alkyl, hydroxy-c1-6-alkyl, c1-6-alkoxy-c1-6-alkyl, or carboxy-c1-6-alkyl; and z2 represents c1-6-alkyl, amino-c1-6-alkyl, c1-6-alkylamino-c1-6-alkyl, di(c1-6-alkyl)amino-c1-6-alkyl, hydroxy-c1-6-alkyl, c1-6-alkoxy-c1-6-alkyl, or carboxy-c1-6-alkyl, z1 and z2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to z1 and z2.. .
|Methods and compositions for treating luekemia|
A combination of a bcr-abl inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.. .
|Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|
medicaments for the treatment of the b-cell chronic lymphocytic leukemia, which are inhibitors of casein kinase 1.
|Primer set for detecting bovine leukemia virus and use thereof|
A forward primer of a primer set in accordance with the present invention for detecting blv is a mixture of (1) a first primer consisting of a polynucleotide including 15 or more successive bases including the 16th c in the base sequence of seq id no: 1 and (2) a second primer consisting of a plurality of kinds of polynucleotides including at least the first to 15th bases in the base sequence of seq id no: 2. Two or more of m, n, y, k, and d which are included in the second primer are each a degenerate base which specifies two or more kinds of bases, and the second primer includes at least 10 kinds of polynucleotides including at least the first to 15th bases in the base sequences of seq id nos: 3 to 12..
Riken Genesis Co., Ltd.
|Genome capture and sequencing to determine genome-wide copy number variation|
Provided herein is a capture library for target enrichment of sequences of interest from a genome dna sample. The capture library comprises a plurality of capture oligos tiling a plurality of capture regions evenly-spaced along a genome.
Florida State University Research Foundation
Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof
The present invention relates to acyl-hydrazone compounds, in particular 3,4,5-trimethoxyphenyl-hydrazide derivatives, as well as the oxadiazole analogs thereof and other similar compounds, and to the pharmaceutical use of the same for the treatment of various diseases associated with cell proliferation, such as leukemias, including acute lymphoblastic leukemia (all), tumours and inflammation. Acyl-hydrazones have been obtained having activity similar to that of the compound used as a standard in experiments (colchicine).
Universidade Federal De Santa Catarina
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of sns-595.
Sunesis Pharmaceuticals, Inc.
Compounds and methods for kinase modulation, and indications therefor
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein.
Molecular design and chemical synthesis of pharmaceutical-ligands and pharmaceutical-pharmaceutical analogs with multiple mechanisms of action
Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs.
The present invention in one embodiment provides a compound of formula (i): or a pharmaceutically acceptable salt thereof, wherein the variables shown in formula (i) are as defined in the specification. The compound of formula (i) is useful for the treatment of diseases such as a disease selected from the group consisting of multiple myeloma, solid tumors, lymphoma, and leukemia..
Concert Pharmaceuticals Inc.
Method, reagents, and kits for detecting minimal residual disease
The invention relates to the field of minimal residual disease (mrd) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as b-cell precursor acute lymphoblastic leukemia (bcp-all), b-cell chronic lymphocytic leukemia (b-cll), and multiple myeloma (mm). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≧8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 10−4, even down to 10−5.
Erasmus University Medical Center Rotterdam
Novel combination treatment for acute myeloid leukemia (aml)
The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the mdm2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly aml.. .
Hoffmann-la Roche Inc.
Compositions and methods for the treatment of severe pain
The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Chronic lymphocytic leukemia prognosis and treatment
Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one apoe4 allele in the subject, the presence of an apoe4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoe4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia.
Compositions, methods and kits for treating cancer
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin j3 or a derivative thereof, or a prostaglandin d receptor (dp) agonist. The compositions may further include a second anti-cancer drug.
The Penn State Research Foundation
Methods for treating cancers
Or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer.
Use of an h4 agonist molecule to treat acute leukemia
The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (amino-7 triethoxy-4,5,6 oxo-1 dihydro-1,3 isobenzofurannyl-3)-1 methoxy-8 methyl-2methylenedioxy-6,7 tetrahydro-,2,3,4 isoquinoleine or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type b leukemia.. .
Usp37 inactivation as a treatment for plzf/rara-associated acute promyelocytic leukemia
Method of regulating the stability and/or the level of the fusion protein plzf/rara are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein plzf/rara.
Methods and compositions for the prognosis and treatment of relapsed leukemia
The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample.
New York University
Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
The present invention provides polypeptides with histone h3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest.
The University Of North Carolina At Chapel Hill
Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.. .
Albert Einstein College Of Medicine Of Yeshiva University
Inhibition of leukemic stem cells by pp2a activating agents
A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula i: i wherein r1 is independently selected from hydrogen and methyl; r2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; x is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of formula ii: ii wherein r1 is a c6-c12 alkyl or c6-c12 alkoxy group; r2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and r3 is an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof..
Ohio State Innvation Foundation
The disclosed molecules are inhibitors of bcr-abl and src kinases. The molecules are cytotoxic to gleevec resistant cells.
Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
The invention relates to antibodies directed against human leukemia inhibitory factor (lif) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease.
Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (icrea)
Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
In one aspect, the invention relates to compositions comprising bcr-abl tyrosine kinase inhibitors and artemisinin analogues, derivatives thereof, or related compounds, which are useful as in treating philadelphia chromosome positive leukemias; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with bcr-abl dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Evaluation of cancer diagnosis following cancer radiotherapy and potentiation of cancer radiotherapy
A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy..
Glut-1 as a receptor for htlv envelopes and its uses
The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of primate t-cell leukemia virus (ptlv), or fragments or variants thereof named receptor binding domain ligands (rbd) selected for their ability to bind specifically to the nutrient transporter glut1.. .
Methods to impair hematologic cancer progenitor cells and compounds related thereto
Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (aml), chronic myelogenous leukemia (cml) and chronic lymphoid leukemia (cll). Interleukin-3 receptor alpha chain (il-3rα or cd123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells.
In vitro culture conditions for t-cell acute lymphoblastic leukemia/lymphoma
We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially t-cell acute lymphoblastic leukemia lymphoma (t-all), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.. .
The Brigham And Women's Hospital, Inc.
Administration of angiocidin for the treatment of cancer
Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype..
Temple University Of The Commonwealth Of Higher Education
Method of treatment with prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin in-2-1h-one and derivatives thereof
A prodrug can have a structure of formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis, candidiasis (moniliasis), candida albicans, tinea (pityriasis) vesicolor, malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma..
The University Of Kansas
S100 protein inhibitors for treating leukemia
The present invention relates to a compound, composition and method for reducing or inhibiting the differentiation or development of progenitor blood cells into malignant cells, leukemia cells or physiologically pathological cells. Particularly, the invention describes the use of inhibitors of s100 proteins, including myeloid related proteins.
Diagnosis and treatment of cancer expressing ilt3 or ilt3 ligand
The present invention relates to methods of using the expression of iltl3 ligand or ilt3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ilt3-ligand expressing cancers, such as t-cell acute lymphoblastic leukemia (t-cell acute lymphoblastic leukemia), for example by administering ilt3, the extracellular domain of ilt3 or ilt3fc conjugated to a cytotoxic agent to kill the targeted cancer cell.
The Trustees Of Columbia University In The City Of New York
Leukemic stem cell ablation
A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (tki) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.. .
Chemgenex Pharmaceuticals, Inc.
Compositions and methods for treating cancers
The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the cdx2-klf4 signaling pathway to treat myelodysplastic syndromes (mds), acute myelogenous leukemia (aml), acute lymphocytic leukemia (all), adult t-cell leukaemia (atll), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the cdx2-klf4 signaling pathway..
Aptose Biosciences Inc.
Method for ex-vivo purging in autologous transplantation
The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of fasl to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (asct) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating hodgkin's disease.
Topotarget Switzerland Sa
Method of treatment of philadelphia chromosome positive leukemia
The invention provides a method for the treatment of ph+ leukemia in a patient comprising administering to the patient (i) a bcr-abl tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of ph+ leukemia in a patient; and a composition for the treatment of ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii).
Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. Acute myeloid leukemia (aml) and related cancers.
Substituted aminopyrimidine compounds and methods of use
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not limited to leukemias and solid tumors, in mammals, especially humans..
Calitor Sciences, Llc
Substituted aminopyrimidine compounds and methods of use
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.